A Phase 2 interventional study of CF101 and Placebo in Rheumatoid Arthritis, sponsored by Can-Fite BioPharma. Completed at 26 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-29.
Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Arthritis, Rheumatoid with a site in Ukraine — 4 open to participants now, 8 under way, 1 of them phase 3. Arthritis, Rheumatoid · Ukraine.
Among the 118 studies in Arthritis, Rheumatoid with a site in Ukraine, this one is the 82nd largest by enrollment of the 115 interventional ones that give a count, is one of 6 that started in 2008, is one of 56 in phase 2, and was the 19th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 118 studies in Arthritis, Rheumatoid with a site in Ukraine are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Ukraine, United States, Belgium and 8 more countries
Ages 18–65
AstraZeneca · Sites in Ukraine, United States, Argentina and 14 more countries
Ages 18+
AstraZeneca · Sites in Ukraine, United States, Australia and 7 more countries
Ages 18–65
Lifordi Immunotherapeutics, Inc. · Sites in Ukraine, Australia, Georgia and 2 more countries
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 60 · Phase 3 47 · Phase 4 3
First in 2002; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 409 across the 115 interventional studies, 809 across the 3 observational. Of the 109 that completed or were terminated, 81 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
118 of 118 have an industry lead sponsor. The 10 most frequent:
Can-Fite BioPharma is the lead sponsor of 22 studies on the registry; 5 are open to participants now.
Can-Fite BioPharma has 4 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Rheumatoid with a site in Ukraine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052032Candid TherapeuticsAn Open-label Study of CND261 in Seropositive Rheumatoid Arthritis | 2027-06-01 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT07276581AstraZenecaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 118 studies in Arthritis, Rheumatoid with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.
This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled, dose-finding study in which patients with active RA despite receiving methotrexate for at least 6 months (at unchanged doses for >=2 months) will be randomized to the addition of either CF101 0.1 mg, CF101 1 mg, or placebo given orally q12h for 12 weeks. Screening examinations will occur within 1 month prior to dosing. Washout of other disease-modifying antirheumatic drugs (DMARDs) (with the exception of hydroxychloroquine), including biological agents, will occur prior to dosing; if washout is necessary, patients must re-qualify for inclusion following the washout. Doses of nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids must be stable for >=1 month prior to dosing and remain so during protocol participation. Disease activity will be assessed using swollen and tender joint counts, physician and patient global assessments (by visual analog scale, VAS), patient reported pain (by VAS), a Health Assessment Questionnaire (HAQ) Disability Index (DI), Westergren erythrocyte sedimentation rate (ESR, Screening, Weeks 0 and12), and C-reactive protein (CRP) levels. Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, and 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CF101 0.1 mg was given orally q12h
Drug: CF101
CF101 1 mg was given orally q12h
Drug: CF101
Matched placebo was given orally q12h
Drug: Placebo
orally q12h
Also known as: IB-MECA
orally q12h
ACR20 at Week 12
Number of patients that achieved 20% response at week 12 in American College of Rheumatology Criteria
Time frame: 12 weeks
ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters
ACR20/50/70 responses over time (intent-to-treat \[ITT\], last observation carried forward \[LOCF\]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses
Time frame: 12 weeks
| Milestone | CF101 0.1mg | CF101 1mg | Placebo |
|---|---|---|---|
| Started | 82 | 87 | 84 |
| Completed | 66 | 68 | 65 |
| Not completed | 16 | 19 | 19 |
| Withdrew: Adverse event | 2 | 3 | 3 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Regulatory decision in bulgaria | 10 | 14 | 13 |
| Withdrew: Change in therapy | 2 | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 |
Number of patients that achieved 20% response at week 12 in American College of Rheumatology Criteria
| participants | CF101 0.1mg | CF101 1mg | Placebo |
|---|---|---|---|
| ACR20 at Week 12 | 29 | 34 | 33 |
ACR20/50/70 responses over time (intent-to-treat \[ITT\], last observation carried forward \[LOCF\]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CF101 0.1mg | — | 3/82 (3.7%) | 2/82 (2.4%) |
| CF101 1mg | — | 2/87 (2.3%) | 5/87 (5.7%) |
| Placebo | — | 3/84 (3.6%) | 1/84 (1.2%) |
| Event | CF101 0.1mg | CF101 1mg | Placebo |
|---|---|---|---|
| Nausea and DiarrhoeaGastrointestinal disorders | 1/82 | 2/87 | 0/84 |
| PancytopeniaBlood and lymphatic system disorders | 1/82 | 0/87 | 0/84 |
| Alanine aminotransferase and Aspartate aminotransferase increasedInvestigations | 1/82 | 1/87 | 1/84 |
| Microcytic anemiaBlood and lymphatic system disorders | 0/82 | 0/87 | 1/84 |
| Eyelid oedemaEye disorders | 0/82 | 0/87 | 1/84 |
| Event | CF101 0.1mg | CF101 1mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/82 | 5/87 | 1/84 |
| Age, Categorical(Participants) | CF101 0.1mg | CF101 1mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 66 | 69 | 69 | 204 |
| >=65 years | 16 | 18 | 15 | 49 |
| Age, Continuous(years) | CF101 0.1mg | CF101 1mg | Placebo | Total |
|---|---|---|---|---|
| Median | 55 (24 to 75) | 54 (25 to 75) | 54 (33 to 73) | 54 (24 to 75) |
| Sex: Female, Male(Participants) | CF101 0.1mg | CF101 1mg | Placebo | Total |
|---|---|---|---|---|
| Female | 68 | 64 | 71 | 203 |
| Male | 14 | 23 | 13 | 50 |
| Region of Enrollment(participants) | CF101 0.1mg | CF101 1mg | Placebo | Total |
|---|---|---|---|---|
| Serbia | 22 | 20 | 20 | 62 |
| Ukraine | 22 | 26 | 26 | 74 |
| Israel | 9 | 9 | 8 | 26 |
| Bulgaria | 29 | 32 | 30 | 91 |
The record gives a start of Feb 2008, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 6 years after primary completion. A results delay was requested in Jun 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CF101